| Literature DB >> 26126123 |
Ragul Gowthaman1, Sven A Miller1, Steven Rogers1, Jittasak Khowsathit1, Lan Lan1, Nan Bai1, David K Johnson1, Chunjing Liu1, Liang Xu1, Asokan Anbanandam1, Jeffrey Aubé1, Anuradha Roy1, John Karanicolas1.
Abstract
Protein-protein interactions represent an exciting and challenging target class for therapeutic intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets presented by "traditional" drug targets, and crystal structures reveal that inhibitors typically engage these sites using very shallow binding modes. As a consequence, modern virtual screening tools developed to identify inhibitors of traditional drug targets do not perform as well when they are instead deployed at protein interaction sites. To address the need for novel inhibitors of important protein interactions, here we introduce an alternate docking strategy specifically designed for this regime. Our method, termed DARC (Docking Approach using Ray-Casting), matches the topography of a surface pocket "observed" from within the protein to the topography "observed" when viewing a potential ligand from the same vantage point. We applied DARC to carry out a virtual screen against the protein interaction site of human antiapoptotic protein Mcl-1 and found that four of the top-scoring 21 compounds showed clear inhibition in a biochemical assay. The Ki values for these compounds ranged from 1.2 to 21 μM, and each had ligand efficiency comparable to promising small-molecule inhibitors of other protein-protein interactions. These hit compounds do not resemble the natural (protein) binding partner of Mcl-1, nor do they resemble any known inhibitors of Mcl-1. Our results thus demonstrate the utility of DARC for identifying novel inhibitors of protein-protein interactions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26126123 PMCID: PMC4707132 DOI: 10.1021/acs.jmedchem.5b00150
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446